ImmunityBio, Inc. (IBRX) Stock

About ImmunityBio, Inc.

ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.

ImmunityBio, Inc. is led by CEO Richard Gerald Adcock, employs 691 people, headquartered in San Diego, US, publicly traded since 2015.

ImmunityBio, Inc. (IBRX) stock trades at $8.22 with a market capitalization of $8.71B. The stock is valued at a negative price-to-earnings (P/E) ratio of -10.18, reflecting a net loss over the last twelve months, a negative price-to-book of -9.94, reflecting negative shareholders' equity, price-to-sales of 63.35. Over the past 52 weeks the stock has ranged between $1.95 and $12.43, and currently trades 33.9% below its 52-week high.

On profitability, ImmunityBio, Inc. generates a return on equity (ROE) of 134.99% (not meaningful, as shareholders' equity is negative), return on capital employed of -45.63%, an operating margin of -1.58%, a net profit margin of -598.56%.

Official website: immunitybio.com

ImmunityBio, Inc. by the numbers, 2016–2025

Between 2016 and 2025 ImmunityBio, Inc. reported revenue of $0 rising to $113.0M. Compounded, revenue has grown 157.4% a year over five years, —% over three, 653.3% over the last twelve months. Net profit fell to $-351.0M.

Operating margin went from -282954.5% in 2016 to -226.0% in 2025, a gain of 282728.5 percentage points. The most recent net margin is -598.56%. On a trailing twelve-month basis to Jun '26, revenue is $165.0M and net profit $-992.0M.

Borrowings rose from $8.0M to $878.0M, cash from operations was $-305.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged 98.2% over five years, and was 70.2% in the most recent year.

The share price itself has compounded at -10.9% a year over five years, 52.7% over three, 244.1% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

ImmunityBio, Inc. (IBRX) — frequently asked questions